Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06002607 · ClinicalTrials.gov registry record

Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections

A clinical trial of Necrotizing Soft Tissue Infection, sponsored by University of California, Irvine.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT06002607 is a study of Necrotizing Soft Tissue Infection that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 50 participants, below the 331-participant average among 3 other Necrotizing Soft Tissue Infection trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06002607, a study of Necrotizing Soft Tissue Infection, is actively recruiting participants, sponsored by University of California, Irvine.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

Necrotizing soft tissue infection (NSTI) is a devastating disease that results in a high rate of in-hospital complications and despite advances in critical care, wound care, and early intervention, NSTI continues to be associated with a mortality rate of nearly 30%. The antibiotics used in this treatment are Clindamycin, Vancomycin, Piperacillin Tazobactam; these antibiotics may be administered combined or individually, based on individualized patient treatment. Although one of the tenets of management for NSTI is early broad-spectrum intravenous antibiotics (listed above), the duration of antibiotics needed is not well defined. Currently, there exists wide variation in the duration of antibiotics for NSTI ranging between 2-16 days. The objective of this study is to evaluate the safety of a shorter course of antibiotics hypothesizing that a short duration of antibiotics for 48-hours after source-control is achieved will have similar risk of morbidity and mortality compared to a 7-day course of antibiotics post source control. A second aim of this study will be to identify if serum procalcitonin levels/ratio correspond to resolution of systemic infection in patients with NSTI.

Interventions

  • OTHER Antibiotic duration (short course)
  • OTHER Antibiotic duration (extended course)

Study Locations (1)

California

  • University of California Irvine Medical Center - Orange

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-12-28
Est. Completion 2026-12-01

Sponsor

University of California, Irvine

368 total trials

What the Registry Record Tells You About NCT06002607

The ClinicalTrials.gov registry entry for NCT06002607 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 331-participant average among 3 other Necrotizing Soft Tissue Infection trials with a reported enrollment target (85% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Necrotizing Soft Tissue Infection appearing as the primary indexed condition, and to 2 interventions - of which Antibiotic duration (short course) is the first listed.

NCT06002607 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06002607 about?

NCT06002607 is a clinical study titled "Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections". Necrotizing soft tissue infection (NSTI) is a devastating disease that results in a high rate of in-hospital complications and despite advances in critical care, wound care, and early intervention, NSTI continues to be associated with a mortality rate of nearly 30%. The antibiotics used in this trea...

What is the current status of trial NCT06002607?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2023-12-28. Estimated completion is 2026-12-01.

What conditions does trial NCT06002607 study?

This clinical trial studies the following conditions: Necrotizing Soft Tissue Infection.

What interventions are being tested in trial NCT06002607?

The interventions under investigation include: Antibiotic duration (short course) (OTHER), Antibiotic duration (extended course) (OTHER).

Who is sponsoring clinical trial NCT06002607?

This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06002607 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Necrotizing Soft Tissue Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.